Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO Annual Meeting, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.

June 6, 2016

Although the field is in its infancy with regard to clinical data, there is increasing interest in combining checkpoint inhibitor therapy with surgery and/or radiotherapy in head and neck cancers. 

Read more
June 6, 2016

Drug development in oncology is providing much-needed new therapies to patients living with cancer. 

Read more
June 6, 2016

A proprietary plasma DNA genomic sequencing platform demonstrated high sensitivity and positive predictive value and detected mutation sequences that confer resistance to therapy.

Read more
June 6, 2016

Results from the FAST study demonstrated that IMAB362, an antibody against claudin, a tight junction protein, significantly prolonged median PFS and OS in gastric cancers. 

Read more
June 7, 2016

The costs of cancer drugs can vary widely around the world and appear to rise unpredictably and irrespective of typical market forces from the time of their launch. 

Read more
June 7, 2016

Intensification of myeloablative therapy with tandem autologous stem cell transplant (ASCT) improved the probability of survival in patients with high-risk neuroblastoma, with no increase in toxicity, according to a Late Breaking Abstract (LBA3).

Read more
June 6, 2016

Pembrolizumab exhibited clinically significant antitumor activity against recurrent or metastatic head and neck squamous cell carcinoma in a phase II clinical trial. 

Read more
June 6, 2016

A cytarabine and daunorubicin liposomal drug delivery platform outperformed 7+3 drug delivery in a phase III trial for secondary AML. 

Read more
June 6, 2016

A large study found that the individual surgeon and the institution exert greater influence on whether patients undergo mastectomy versus lumpectomy compared with all other clinical and demographic variables, except for tumor size and nodal status.

Read more
June 6, 2016

A study demonstrated that SRS following surgery was noninferior to WBRT for treatment of 1-4 brain metastases, but had a more favorable safety profile, especially with respect to cognitive outcomes.

Read more
June 6, 2016

An education session discussing biomarker identification in prostate cancer, potential future clinical applications for biomarkers, and the steps needed to make potential advances a reality. 

Read more
June 6, 2016

Results from the OCAT study, which evaluated whether intensification of adjuvant radiotherapy with concurrent chemotherapy or accelerated radiotherapy improves outcomes among patients with locally advanced, resectable, squamous cell carcinoma of the oral cavity.

Read more
June 6, 2016

In a phase III trial, nivolumab demonstrated a “significant improval in survival” in patients with recurrent head and neck squamous cell carcinoma (HNSCC), compared with therapy of the investigator’s choice. 

Read more
June 6, 2016

Results from the phase III ETNA study concluded there was no statistical difference in the pCR rate between neoadjuvant nab-paclitaxel and paclitaxel both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Read more
June 6, 2017

Maintenance rituximab failed to prolong progression or improve survival compared with observation in an older group of patients with mantle cell lymphoma who underwent induction therapy with bendamustine/rituximab. 

Read more
June 6, 2016

CRITICS reports on which adjuvant strategy, chemotherapy or chemoradiotherapy, provides better clinical outcomes for patients with resectable gastric cancer. What’s next for these patients? 

Read more
June 6, 2016

PILLAR-2 failed to meet its primary endpoint of improved disease-free survival (DFS) with adjuvant everolimus in patients with poor-risk DLBCL. However, trends favoring everolimus for overall survival and lymphoma-specific survival and for DFS in selected subgroups were observed.

Read more
June 6, 2016

First-line checkpoint inhibitor atezolizumab could be new standard of care for cisplatin-ineligible patients with metastatic urothelial carcinoma. 

Read more
June 6, 2016

Extending aromatase inhibitor therapy beyond the standard 5 years out to 10 years for postmenopausal women with HR-positive early breast cancer significantly improves disease-free survival over placebo.

Read more
June 6, 2016

Results from a phase I study conducted in patients with relapsed or refractory metastatic disease revealed that single-agent treatment with the antibody-drug conjugate delivered a powerful blow to tumors bearing delta-like protein 3.

Read more